1	Association Between Somatic PIK3CA Mutations and Ancestry in
2	South Asia: Prognostic Insights From a Sri Lankan Breast
3	Cancer Study
4	Tharini Ruwinya Cabraal ^{1*} , Iranthi Kumarasinghe ^{2¶} , Ranga Perera ^{2¶} , Jayantha Balawardane ^{2¶} ,
5	Sameera Viswakula ³ ¶, Nandika Perera ⁴ ¶, Gayani Harendra Galhena ^{1*}
6	1. Centre for Immunology and Molecular Biology, Department of Zoology &
7	Environmental Sciences, Faculty of Science, University of Colombo, Colombo, Sri
8	Lanka
9	2. University Hospital, General Sir John Kotelawala Defence University, Colombo, Sri
10	Lanka
11	3. Department of Statistics, Faculty of Science, University of Colombo, Colombo, Sri
12	Lanka
13	4. Genetech Molecular Diagnostics, Colombo, Sri Lanka
14	
15	*Corresponding Authors:
16	Prof. Gayani Harendra Galhena
17	Email: gayani@zoology.cmb.ac.lk (GHG)
18	ORCID: https://orcid.org/0000-0002-1617-6612
19	
20	Tharini Ruwinya Cabraal
21	Email: <u>tharinicabraal@gmail.com</u>
22	ORCID: https://orcid.org/0009-0003-8943-0110
23	

24 ¶ These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract (299 words)

26 Background

The *PIK3CA* oncogene is one of the most mutated oncogenes in breast cancer, with ancestrylinked variations reported globally. The study aimed to discern the prevalence and prognostic role of *PIK3CA* mutations in Sri Lankan breast cancer patients for the first time, focusing on the correlation between somatic mutations and patient ancestry in an exclusively South Asian

31 cohort of breast cancers.

32 Materials & Methods

- 33 A qPCR-based genetic analysis was performed on DNA from formalin-fixed, paraffin-
- 34 embedded (FFPE) tissue samples of 63 clinically diagnosed, female, Sri Lankan breast cancer
- 35 patients using the QClamp® *PIK3CA* Mutation Detection Test for the hotspot mutations of
- 36 *PIK3CA* (i.e., H1047R, E545K, E542K) followed by a statistical analysis. Patient samples
- 37 and clinical data were fully anonymized, with no identifying information available to authors
- 38 at any point of the study.

39 **Results**

- 40 Somatic missense *PIK3CA* mutations H1047R and E542K, were detected in 17.46% of the
- 41 cohort. E545K mutation was not detected. The observed mutations were associated with an
- 42 increased risk of lymph node (LN) metastasis (p=0.036, OR 9.60) and reduced recurrence-
- 43 free survival (RFS) (p<0.001, HR 26.19). In addition, LN metastasis (p=0.026, HR 123.94)
- 44 and a high Ki67 index (p=0.029, HR 79.69) were individually associated with reduced RFS.
- 45 All three factors above- presence of a *PIK3CA* mutation, LN metastasis and a high Ki67
- 46 index- in combination, were also associated with reduced RFS (p<0.001). Further analysis
- 47 revealed a significant association between patient ancestry and *PIK3CA* mutation status
- 48 (p=0.028).

49 **Conclusion**

- 50 Despite being a pilot study, the findings suggest that *PIK3CA* may serve as a potential
- 51 prognostic biomarker in Sri Lankan breast cancer patients, with ancestry-linked variations
- 52 potentially influencing metastatic outcomes. These results bring out the importance of
- 53 integrating PI3K inhibitors into the therapeutic management of breast cancers in Sri Lanka
- 54 after validating these findings in a functional study using a larger cohort.

55 Introduction

Breast cancer is the most commonly diagnosed cancer in women worldwide [1]. Asian women,
particularly those in developing countries, often have a poorer prognosis for breast cancer, with
higher cancer grades and stages as well as an earlier onset of the disease [2].

59 Breast cancer has distinct molecular subtypes that are categorized based on the 60 immunohistochemical (IHC) expression of steroid hormone receptors (SHR), including 61 estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 62 receptor 2 (HER2/*ERBB2* or HER2/*neu*). These subtypes are Luminal A, Luminal B, HER2-63 positive (HER2+), and triple-negative breast cancer (TNBC) [1].

64 More than 85% of breast cancers are sporadic, primarily caused by somatic mutations [3]. 65 These mutations in oncogenes (OGs) and tumor suppressor genes (TSGs) often initiate 66 tumorigenesis [4]. Breast cancer tumorigenesis has been linked to mutations in several cell 67 signaling pathways crucial for normal development such as the PI3K/AKT/mTOR pathway, 68 commonly referred to as the PI3K pathway. Genetic hyperactivation of this pathway is one of 69 the most common driver mechanisms in breast cancer, often through alterations to its 70 components like p110 α (encoded by the phosphatidylinositol-4,5-bisphosphate 3-kinase 71 catalytic subunit alpha gene/PIK3CA; NCBI Gene ID 5290), p110β, and p85α [1,5,6].

Approximately 30% of the mechanisms that over-activate PI3K signaling are due to somatic mutations in the *PIK3CA* oncogene [5], making it the most commonly mutated oncogene in breast cancer [6-8]. While *PIK3CA* mutations can occur across the p110 α subunit, about 80% are caused by the three hotspot mutations clustered in two domains of p110 α : E545K and E542K in the helical domain encoded by exon 9, and H1047R in the kinase domain encoded by exon 20. Among these, H1047R is the most frequently detected *PIK3CA* mutation, while
E542K is the least prevalent [9].

Studies have shown that between 10 to 45% of all human breast cancers harbor *PIK3CA* driver
mutations, with the exact percentage varying based on the studied population and ancestry [510]. Activating mutations of *PIK3CA* are reported in nearly 42% of SHR+/HER2-, 31% of
HER2+ and 16% of TNBC tumors [5].

83 Importantly, the presence of *PIK3CA* mutations has been associated with poorer prognostic 84 outcomes, especially in ER+ cases [11]. Numerous studies illustrate that *PIK3CA* mutations 85 are linked with resistance to various therapies, including endocrine therapy, chemotherapy, 86 radiotherapy, anti-HER2 therapy and immunotherapy. This resistance negatively affects all 87 available treatment modalities for all breast cancer subtypes, with more pronounced effects in 88 advanced and metastatic cases [5,7-10,12]. These mutations also promote cell division and 89 inhibit apoptosis in TNBC cells, leading to resistance to their primary treatment option: 90 chemotherapy [12]. In addition to their role in treatment resistance, accumulating evidence 91 suggests a strong association between PIK3CA mutations and tumor recurrence, poor relapse/recurrence-free survival (RFS), and/or overall survival (OS), particularly in 92 93 postoperative Asian patients with metastatic SHR+/HER2- breast cancers [9,11,13-15]. 94 Despite extensive research, the overall relationship between PIK3CA mutations and the 95 clinicopathological profile of breast cancer patients remains controversial, with conflicting 96 findings across various patient populations, such as observed associations of PIK3CA 97 mutations with longer RFS and/or OS [16,17].

98 Recent advances in genomic studies have provided significant insights into the relationship 99 between genetic ancestry and somatic mutations across cancer types via changes in the 100 germline [18-22]. In particular, the *PIK3CA* oncogene is reported as one of the top two genes

101 observed in breast cancers, whose somatic mutations have shown significant ancestry-linked 102 differences in several global studies predominantly involving patients from European and 103 African ancestries [19-21]. However, Asian populations, particularly those of South Asian 104 descent, remain highly underrepresented in these studies, limiting a comprehensive 105 understanding of ancestry-driven somatic mutations in the region [22].

Sri Lanka is a unique island nation in the Indian Ocean with a rich tapestry of ethnic diversity.
Over 70% of the population is composed of Sinhalese, descendants of Indo-Aryan ancestry,
found exclusively in Sri Lanka [23]. Other major ethnic groups include Tamils and Moors, who
trace their roots to Dravidian ancestry, and Burghers, descendants of European colonists in Sri
Lanka, who also share Indo-Aryan ancestry [23,24]. This distinct combination of Indo-Aryan
and Dravidian ancestries, together with its centralized geographical location, particularly
during the maritime silk route, makes Sri Lanka a melting pot of genetic diversity.

113 Breast cancer is the most frequently diagnosed cancer among Sri Lankan women [25]. As a 114 developing, lower-middle income island nation in the Indian Ocean, Sri Lanka has limited research on breast cancer trends and genetic markers, despite a significant rise in incidence and 115 116 mortality rates over time [26,25]. To the best of our knowledge, no studies have been conducted 117 on the prevalence and prognostic outcomes of *PIK3CA* mutations and their correlations with 118 ancestry in breast cancer patients of Sri Lanka. Given the mutational spectrum of *PIK3CA* and 119 its impact on the clinicopathological profile and prognosis of breast cancer, which varies 120 significantly depending on the population and their ancestry, it is important to elucidate the 121 current status of Sri Lankan breast cancer patients in this context – an area that remains largely 122 unexplored.

123 This study was therefore designed to achieve the overarching aim of cataloguing hotspot 124 mutations in the *PIK3CA* oncogene within a cross-section of Sri Lankan breast cancer patients

125 that includes all different ancestral groups. Using DNA extracted from tumor tissues obtained 126 at the point of diagnosis, we aimed to correlate the detected mutations with specific 127 clinicopathological characteristics and ultimately assess the prognostic potential of PIK3CA 128 mutations using RFS as a key metric. Given that the Sinhalese population is found nowhere else in the world (except for few migrant individuals), results from this study offer a rare 129 130 opportunity to explore how ancestral genetic makeup in an island nation intersects with somatic mutations, such as those in the *PIK3CA* oncogene. This study managed to successfully catalog 131 132 PIK3CA mutations in our cohort of Sri Lankan breast cancer patients and deduced their impacts 133 on disease prognosis while addressing the critical gap on the implications of ancestry on 134 somatic mutations in a purely South Asian cohort of breast cancer patients, for the first time.

135 Materials and methods

136 **Patient samples**

Ethical approval for the analysis of an existing set of formalin-fixed paraffin-embedded (FFPE)
breast tumor biopsy samples and fully anonymized medical records of the relevant patients was
obtained from the Ethics Review Committee of the Institute of Biology, Sri Lanka (ERC
IOBSL 303 07 2023, S1 Fig). This retrospective study was conducted in compliance with the
REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) and ICMJE
(International Committee of Medical Journal Editors) guidelines.

The fully anonymized database of breast cancer patient records from the Diagnostics Laboratory at the University Hospital of General Sir John Kotelawala Defense University was accessed on the 27th of August 2023. All patient data were fully anonymized, ensuring no patient identifiers were available to the authors at any stage of the research. Using this database, medical records of breast cancer patients treated at the University Hospital of General Sir John Kotelawala Defense University from 2019 to 2023, who met the inclusion criteria (Fig 1) were selected for the study. The corresponding FFPE blocks were retrieved from the hospital's diagnostics laboratory and stored at room temperature until further analysis. Clinicopathological data and follow-up information of these patients ranging from 1 to 5 years post-diagnosis were collected from the hospital database.

To ensure patient anonymity, medical and follow-up data of individual patients were recorded, and the samples were identified exclusively using identification numbers assigned to each sample for the purpose of research. Therefore, as authors did not have access to information that could identify individual participants during or after data collection, total anonymity of patient identity was maintained throughout the study.

158 Fig 1. Flowchart of patient enrollment, inclusion criteria, and study workflow

159 **DNA extraction and hotspot mutation assay**

160 Genomic DNA was extracted from FFPE samples using the QIAamp DNA FFPE Tissue Kit 161 according to the manufacturer's instructions (Cat. No. 56404; Qiagen, Hilden, Germany) and assessed for quality and quantity using the Thermo ScientificTM NanoDropTM One 162 163 Spectrophotometer. The three hotspot mutations of the PIK3CA oncogene- H1047R, E545K, and E542K- were genotyped in 63 of the selected samples using the QClamp® PIK3CA 164 165 Mutation Detection Test Kit (Cat. No. DC-10-1072R; DiaCarta, CA 94588, USA), which 166 utilized a Xeno-nucleic acid (XNA)-based mutation-specific quantitative real-time polymerase 167 chain reaction (qPCR) method.

168 Endpoint and statistical analysis

169 The prevalence of *PIK3CA* mutations in the study cohort and their associations with 170 clinicopathological features were determined using the χ^2 test. Fisher's exact test was

171 employed for dichotomous features. To enhance the statistical validity and minimize the risk 172 of type I errors, patients were grouped according to significant, widely accepted clinicopathological cutoffs in oncology based on the sample size available for each category 173 174 (S1 Table). In the analysis of ancestry, patients grouped into Indo-Arvan ancestry (Sinhalese 175 & Burghers) were compared to those of Dravidian ancestry (Tamils & Moors). Depending on 176 data normality, either a t-test or Mann-Whitney Test was performed to compare the mean or median of populations for the relevant variables. For specific variables showing significant 177 178 associations, binary logistic regression was used to obtain the odds ratio (OR) and the 95% 179 confidence interval (CI). This binary logistic regression model assumed that there were no 180 significant multicollinearity issues, and all independent variables were linearly related to the 181 log-odds of the dependent variable.

All patients underwent routine clinical examinations at the hospital every 3-6 months, and the clinicopathological variables analyzed were those recorded at the initial diagnosis. Since all patients with survival data (n=42) were alive at the last follow-up, RFS was used as the survival metric instead of OS, and was defined as the time from the date of curative surgery to the clinical diagnosis of recurrence. Events considered in RFS included distant and local invasive recurrence. Patients without survival data were excluded from the survival analysis. The median follow-up time after diagnosis was 37.00 months (0.00–81.19).

The Kaplan-Meier method was used to plot RFS, while the Mantel-Cox log-rank test was applied to compare different subgroups of the variables. Significant parameters identified by the log-rank test (p<0.05) were further analyzed using a univariate Cox proportional hazard regression model. A multivariate model was finally used to analyze the combined effect of all significant associations on RFS. However, for parameters which could not generate a statistically robust Cox proportional hazard regression model due to limited data on survival,only the p-value was reported.

Samples with missing data for the variable of interest were excluded from specific analyses.
All statistical tests were two-sided and a p-value below 0.05 was considered statistically
significant. Analyses were performed using SPSS 25 (Released 2017. IBM SPSS Statistics for
Windows, Version 25.0. Armonk, NY: IBM Corp.) and R (version 4.0.2, R Foundation for
Statistical Computing, Vienna, Austria).

201 **Results**

202 Analysis of the clinicopathological features and ethnicity

203 The studied cohort consisted of 66 patients clinically diagnosed with breast cancer between

204 2019 and 2023. The median age at the time of diagnosis was 58.00 years (S2 Fig).

Table 1 presents several key characteristics of the cohort. Accordingly, IHC analysis revealed that over 80% of the tumors were SHR-positive HER2-negative luminal subtypes, with luminal A and B subtypes occurring in equal proportions. Over 95% of the cohort comprised of Sinhalese patients while the remaining 5% included two Tamil patients, one Moor, and one Burgher patient. This represents only a rough approximation of the actual ethnic distribution in Sri Lanka, where approximately 72% of the population are Sinhalese [23].

- 211 Table 1. Clinicopathological and population characteristics of the cohort
- 212

Age at diagnosis	No. of patients	%
<35	0	0.00
36-45	5	7.58
46-55	20	30.30
56-65	19	28.79
66-75	15	22.73
76-85	6	9.09
>85	1	1.52
Side	No. of patients	%

Table 1 continued

L/S	30	45.45
R/S	36	54.55
Site of the tumor	No. of patients	%
Upper outer quadrant	2	3.03
Upper inner quadrant	14	21.21
Lower inner quadrant	0	0.0
Lower outer quadrant	3	4.55
Central	5	7.58
Clock Positions	22	33.33
Two quadrants	2	3.03
Unknown	18	27.27
Histological type	No. of patients	%
IBC-NST	57	86.36
Invasive mucinous carcinoma	4	6.06
Histological type	No. of patients	%
Invasive lobular carcinoma	2	3.03
Invasive papillary carcinoma	1	1.52
Invasive tubular carcinoma	1	1.52
DCIS	1	1.52
Tumor grade/ differentiation	No. of patients	%
Grade 1/ well-differentiated	22	33.34
Grade 2/ moderately	37	56.06
differentiated		
Grade 3/ poorly differentiated	5	7.57
Unknown	2	3.03
Tumor size	No. of patients	%
≤2 cm	12	18.18
>2 cm	37	56.06
Unknown	17	25.76
Pathological tumor stage	No. of patients	%
Tis	1	1.52
pT1	10	15.15
pT2	31	46.97
pT3	6	9.09
Unknown	18	27.27
Pathological nodal stage	No. of patients	%
pN0	29	43.94
pN1	13	19.70
Pathological nodal stage	No. of patients	%
pN2	6	9.09
pN3	2	3.03
Unknown	16	24.24
Lymph node metastasis	No. of patients	%
Positive	21	31.82
Negative	29	43.94
Unknown	16	24.24
ER status	No. of patients	%

213

Table 1 continued

ER+	60	90.91
ER-	6	9.09
PR status	No. of patients	%
PR+	46	69.70
PR-	20	30.30
SHR status	No. of patients	%
SHR+	60	90.91
SHR-	6	9.09
HER2 status	No. of patients	%
HER2+	6	9.09
HER2-	59	89.39
Unknown	1	1.52
Receptor based subtype	No. of patients	%
SHR+/HER2-	55	83.34
SHR+/HER2+	4	6.06
Receptor based subtype	No. of patients	<u>%</u>
SHR-/HER2+	2	3.03
SHR-/HER2-	4	6.06
Unknown	1	1.51
Ki67 Proliferation index	No. of patients	%
<20% (low)	30	45.45
$\geq 20\%$ (high)	28	42.42
Unknown	8	12.12
IHC-based molecular	No. of patients	%
subtype		
Luminal A	24	36.36
Luminal B	24	36.36
Luminal (undetermined for	7	10.60
A/B as Ki67 data unavailable)		
HER2 enriched	6	9.09
TNBC	4	6.06
HER2 unknown	1	1.51
Ethnicity	No. of patients	%
Sinhalese	63	95.45
Tamil	1	1.51
Moor	1	1.51
Burgher	1	1.51
Ancestry	No. of patients	%
Indo-Aryan	64	96.96
Dravidian	2	3.03

DCIS: ductal carcinoma in-situ, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, IBC-NST: invasive breast carcinoma of no special type, IHC:immunohistochemical, L/S: left side, pN: pathological nodal stage, PR: progesterone receptor, pT: pathological tumor stage, R/S: Right side, SHR: steroid hormone receptor, Tis: carcinoma in-situ stage, TNBC: triple-negative breast cancer

"Unknown" - samples with data unavailable for the parameter of interest

217 Prevalence of PIK3CA mutations in the cohort

Missense mutations in the *PIK3CA* oncogene were detected in 17.46% (n=11) of the cohort. The mutations observed included H1047R (c.3140A>G) in 81.81% (n=9) and E542K (c.1624G>A) in 18.18% (n=2) of the mutated samples. Notably, both H1047R and E542K mutations were detected in one sample (co-mutation prevalence: 9.09% of the mutated and 1.58% of the total samples). No E545K mutations (c.1633G>A) were detected in the cohort.

223 Association of *PIK3CA* mutations with clinicopathological

224 parameters and ancestry

All *PIK3CA* mutations identified were found in SHR+/HER2- luminal tumors (Table 2). Importantly, a significant association was observed between *PIK3CA* mutational status and lymph node (LN) metastasis, with patients harboring a *PIK3CA* mutation exhibiting 9.60 times higher odds of LN metastasis compared to those without a *PIK3CA* mutation (p=0.036, OR 9.60, 95% CI 1.05-87.78). Notably, a significant association was observed between the ancestry of the patients and the presence of a *PIK3CA* mutation (p=0.028). Other parameters showed no significant association with the mutational status.

232 Table 2. *PIK3CA* mutational status and Ki67 proliferative index in selected

233 clinicopathological and ancestral groups

Parameter	Mutations absent (n)	<i>PIK3CA</i> Mutated (n)	Total (n)	p-value
All	52	11	63	
Age at diagnosis				
\leq 50 years	14	2	16	
> 50 years	38	9	47	0.714
Histological type				
IBC-NST	45	10	55	
Other	7	1	8	1.000

		Table 2 continued		
Tumor grade/				
differentiation				
G1/ well-	17	4	21	
differentiated				
G2 or G3/ moderately	33	7	40	1.000
or poorly				
differentiated				
Tumor size				
$\leq 2 \text{ cm}$	9	2	11	
>2 cm	30	5	35	1.000
Mean (cm) (95% CI)	3.5 (2.8-4.2)	3.2 (1.7-4.7)		
Median (cm) (Range)	3.2 (0.7-	3 (1.1-6.0)		0.994
	12.0)			
Pathological tumor				
stage				
Early stage	32	6	38	
(pT1/pT2)				
Late stage (pT3/pT4)	6	1	7	1.000
Lymph node				
Metastasis				
Negative	24	1	25	
Positive	15	6	21	*0.036
ER status				
ER+	47	11	58	
ER-	5	0	5	0.576
PR status				
PR+	37	7	44	
PR-	15	4	19	0.721
SHR status				
SHR+	47	11	58	
SHR-	5	0	5	0.576
HER2 status				
HER2+	6		6	
HER2-	45	11	56	0.580
Receptor based				
subtype				
SHR+/HER2-	42	11	53	
Other	10	0	10	0.187
Ki67 Proliferation				
index				
<20%	23	5	28	
<u>≥20%</u>	22	5	27	1.000
IHC-based				
molecular subtype				
Luminal	42	11	53	
HER2/TNBC	9	0	9	0.341
Ancestry				
Indo-Aryan	52	9	61	

		Table 2 continued		
Dravidian	0	2	2	*0.028
Parameter	Ki67	Ki67	Total	p-value
	< 20% (Low)	≥20%		I
		(High)		
All	30	28	58	
Age at diagnosis				
\leq 50 years	7	7	14	
>50 years	23	21	44	1.000
Histological type				
IBC-NST	23	27	50	
Other	7	1	8	0.053
Tumor grade/				
differentiation				
G1/ well-	14	5		
differentiated				
G2 or G3/	15	23	38	▲ 0.024
moderately or				
poorly				
differentiated				
Tumor size				
$\leq 2 \text{ cm}$	5	5	10	
> 2 cm	20	12	32	0.714
Mean (cm) (95%	3.3 (2.5-4.2)	3.4 (2.3-		
CI)		4.5)		
Median (cm)	3.0 (1.2-12.0)	3.3 (0.7-		0.884
(Range)		9.3)		
Pathological				
tumor stage				
Early stage	21	14	35	
(pT1/pT2)				
Late stage	2	3	5	0.634
(pT3/pT4)				
Lymph node				
metastasis				
Negative	17	9	26	
Positive	8	8	16	0.353
ER status				
ER+	27	26	53	
ER-	3	2	5	1.000
PR status				
PR+	23	18	41	
PR-	7	10	17	0.390
SHR status				
SHR+	27	26	53	
SHR-	3	2	5	1.000
HER2 status				
HER2+	3	3	6	

		Table 2 continued		
HER2-	26	25	51	1.000
Receptor based				
subtype				
SHR+/HER2-	24	24	48	
Other	6	4	10	0.732
IHC-based				
molecular subtype				
Luminal	24	24	48	
HER2/TNBC	5	4	9	1.000
*: association is signification	nt at 5% level, (OR 9.600, 95% (CI 1.050-87.784	
A · association is signified	nt at 5% laval	OP / 203 05%	CI 1 270 17 708	

ficant at 5% level, OR 4.293, 95% CI 1.279-14.408 CI: confidence interval, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, IBC-NST: invasive breast carcinoma of no special type, IHC: immunohistochemical, LN: Lymph Node, OR: odds ratio, PR: progesterone receptor, pT: pathological tumor stage, SHR: steroid hormone receptor, TNBC: triple-negative breast cancer

236

Associations among other clinical and histopathological 237

238 parameters

- 239 Table 2 also outlines the associations between the Ki67 proliferation index and other
- 240 clinicopathological features. A significant association was identified between Ki67 status and
- 241 tumor grade, with higher Ki67 proliferative indices being linked to a 4.29 times higher
- likelihood of developing moderately or poorly differentiated breast cancers of higher tumor 242
- 243 grades, compared to those with proliferative indices < 20% (p=0.024, OR 4.29, 95% CI 1.28-
- 244 14.41).
- 245 No statistically significant associations were observed between LN metastasis or patient age
- 246 group and other clinicopathological parameters (S2 Table).

Impact of *PIK3CA* mutational status on RFS 247

248 Among patients with survival data, 9.5% (n=4) experienced a relapse in a different organ (e.g.,

249 pelvic bone and lungs) following curative surgery. Three of these patients (75.0%) had PIK3CA

250 mutations, with two harboring the H1047R mutation (50%) and one carrying the E542K 251 mutation (25%).

- 252 The presence of a *PIK3CA* mutation was thereby significantly associated with reduced RFS
- 253 (p<0.001), as shown in the Kaplan-Meier curve (Fig 2A and Table 3). Patients with a *PIK3CA*
- 254 mutation had 26.19 times higher odds of relapse compared to the those without a mutation (HR
- 255 26.19, 95% CI 2.67-256.47). The mean RFS for patients with *PIK3CA* mutations was 26.5
- 256 months.
- 257 Fig 2. Kaplan-Meier survival estimates for relapse-free survival (RFS) stratified by
- 258 PIK3CA mutation status (A), status of lymph node (LN) metastasis (B) and Ki67
- 259 proliferative status (C) while (D) shows the multivariate impact of all above three
- 260 factors *PIK3CA* mutation, LN metastasis and Ki67 index on RFS.
- 261 Fig. 2A: p-value<0.001, HR 26.187, 95% CI 2.674 256.475
- Fig. 2B: p-value=0.026, HR 123.939, 95% CI could not be generated with statistical robustness due to
- small sample size
- Fig. 2C: p-value=0.029, HR 79.688, 95% CI could not be generated with statistical robustness due to
- small sample size
- Fig.2D: p-value=0.00048, HR and 95% CI could not be generated with statistical robustness due to
- small sample size
- 268 HR: hazard ratio, CI: confidence interval
- 269 Table 0. Impact of the overall and specific *PIK3CA* mutation status on relapse-free
- 270 survival (RFS)

	p-value	Hazard Ratio Exp (B)	95% CI
Association	**<0.001	26.187	2.674 - 256.475
between PIK3CA			
mutation & RFS			
	<i>PIK3CA</i> mutated	<i>PIK3CA</i> not mutated	
Mean RFS	26.5	54.5	
(months)			
95% CI of mean	13.99 - 39.01	51.12 - 57.84	

	Tabl	e 3 continued		
Median RFS in	37.00			
months (95% CI)	(0.00-81.91)			
PIK3CA Mutation	Relapse	No relapse	Total	p-value
	(n)	(n)	(n)	
H1047R	2	2	4	
Other	1	1	2	
Total	3	3	6	0.281
**: Association is signi	ficant at 1% level			
CI: confidence interval,	RFS: Relapse-free su	urvival		
"Other" includes the E5	542K mutation and th	ne H1047R/E542K	co-mutation	

271

- 272 However, no significant association was found between individual PIK3CA hotspot mutations
- 273 (H1047R or E542K) and RFS (Table 3).

clinicopathological parameters

Impact of selected clinicopathological features on RFS 274

275 LN metastasis was significantly associated with RFS (Table 4). Patients with LN-positive

276 status had 123.94 times higher hazard of relapse compared to LN-negative patients (p=0.026,

277 HR 123.94; Fig 2B). Additionally, a significant association was observed between Ki67

278 proliferative status and RFS, with patients having higher proliferative indices facing a 79.69

- 279 times higher hazard of relapse compared to those with Ki67 indices <20% (p=0.029, HR 79.69;
- 280 Fig 2C).

281

282 Table 4. Univariate analysis of relapse-free survival (RFS) with selected

284

Parameter	Relapse (n)	No relapse (n)	Total	p-value
All	4	38	42	
Age at diagnosis				
≤50 years	1	10	11	
>50 years	3	28	31	0.772
Histological type				
IBC-NST	3	31	34	
Others	1	7	8	0.701
Tumor grade/				
differentiation				
G1/ well-differentiated	1	13	14	

		Table 4 continued		
G2 or G3/ moderately or	3	23	26	0.717
poorly differentiated	-			
Tumor size				
$\leq 2 \text{ cm}$	1	9	10	
>2 cm	2	21	23	0.941
Mean (cm)	3.164			0.830
Pathological tumor stage	e			
Early stage (pT1/pT2)	3	26	29	
Late stage (pT3/pT4)	0	3	3	0.585
Lymph node metastasis				
Negative	0	19	19	
Positive	3	12	15	*0.026
ER status				
ER+	4	37	41	
ER-	0	1	1	0.769
PR status				
PR+	3	30	33	
PR-	1	8	9	0.805
SHR status				
SHR+	4	37	41	
SHR-	0	1	1	0.769
HER2 status				
HER2+	0	3	3	
HER2-	4	34	38	0.529
Receptor based subtype				
SHR+/HER2-	4	33	37	
Other	0	5	5	0.417
Ki67 Proliferation index				
<20%	0	19	19	
≥20%	4	15	19	▲ 0.029
IHC-based molecular				
subtype				
Luminal A/B	4	33	37	0.450
HER2/INBC		4	4	0.4/8
*: association is significant due to small sample number	at 5% leve	I, HR 123.929, A	A statistically robus	t 95% CI not generated
▲: association is significant	at 5% leve	el, HR 79.688, A	statistically robust	95% CI not generated
due to small sample number		,,,	j	<i>8</i>
CI: confidence interval, ER:	estrogen rec	eptor, HER2: hu	ıman epidermal gro	wth factor receptor 2,
HR: hazard ratio, IBC-NST:	invasive bro	east carcinoma of	f no special type, II	HC:
immunohistochemical, LN: I	Lymph Nod	e, PR: progestero	one receptor, pT: pa	thological tumor stage,
SHR: steroid hormone recept	tor, TNBC:	triple-negative b	reast cancer	

No other clinicopathological characteristics showed significant associations with RFS.

Finally, the multivariate Cox proportional hazard model (Fig 2D) demonstrated a significant
association between the presence of a *PIK3CA* mutation, LN metastasis and a high Ki67 index
with RFS (p<0.001).

292

293 **Discussion**

This study, to our knowledge, is the first to profile *PIK3CA* mutations, assess their prognostic value, and evaluate the implications of patient ancestry on somatic mutations in Sri Lankan breast cancer patients. Despite being a pilot study conducted in an underrepresented island population, our findings lay the groundwork for future research, including meta-analyses in larger cohorts.

299 The analysis of the clinicopathological parameters showed a median age of 58 years at breast 300 cancer diagnosis, higher than the median age reported in a Sri Lankan study done over a decade 301 ago, and higher than those reported from several Southeast Asian countries and Arab countries 302 [26-29]. This could be due to Sri Lanka having one of the fastest ageing populations in the 303 world [26]. The exponentially growing population of older women [26] would thus raise the incidence of breast cancer among this demographic, making it a key factor in the observed age 304 305 shift in diagnosis. However, the fact that the majority of patients were already at stage 2 at the 306 time of diagnosis, even with slow-growing cancers (i.e., luminal A and B), suggests a much 307 earlier onset of the disease. This trend, consistent with other Asian countries, could probably 308 be attributed to similar genetic and sociocultural factors and contrasts with developed Western 309 countries, where median age of diagnosis occurs much later [30].

310 Similar to reports by previous studies conducted in Sri Lanka [31,32], it is noticeable that a 311 majority of the tumors in our cohort were invasive breast carcinomas (IBC-NST) of tumor

312 grade 2 and/or stage II at diagnosis. This could be likely due to the absence of an established 313 screening program aimed at early detection in Sri Lanka, thus reducing the likelihood of the 314 cancer being detected at stage I and worsening disease outcomes [31]. These observations 315 therefore highlight the need for the implementation of an effective screening system for breast 316 cancer in Sri Lanka, to facilitate early diagnosis and ultimately reduce the overall burden of 317 breast cancer in the country. Consistent with both local and global statistics [31-33], most 318 tumors were ER/PR+ and HER2-, confirming that SHR+/HER2- luminal subtypes are the most 319 common in Sri Lanka.

320 One of the study's primary objectives was to catalog *PIK3CA* mutations in the cohort of patients 321 and to detect associations with clinicopathological features. The detection of H1047R and 322 E542K mutations in 17.46% of cases falls within the prevalence range of *PIK3CA* mutations 323 reported in many global studies on breast cancer [5-10]. Notably, this study also provides the 324 first evidence of PIK3CA mutations in Sri Lankan breast cancer patients. India, the closest 325 nation to Sri Lanka both geographically and genetically, reports a *PIK3CA* mutation prevalence of 23.2% [34], closely aligned with our findings. This similarity likely reflects common 326 327 hereditary factors shaped by historical migrations and cultural exchanges, which may have 328 influenced the prevalence of *PIK3CA* mutations in the South Asian region.

Although the predominance of H1047R as the most frequently observed *PIK3CA* mutation mirrors observations in other populations [35], our study reports a much a higher frequency of 81.81% for H1047R among the total *PIK3CA* mutations, compared to the frequency (\approx 58%) reported in other studies [35,36]. A particularly rare and unexpected observation was the absence of the E545K mutation in our cohort, which is commonly reported as a moderately prevalent *PIK3CA* mutation (\approx 10%) in many other global populations [37,38]. This observation aligns with findings from an Iranian study, where the E545K mutation was

336 similarly absent [39]. Given that over 96% of our cohort comprises Sri Lankan Sinhalese and 337 Sri Lankan Burghers (both of Indo-Aryan ancestry), this shared absence is likely to be 338 stemming from a common ancestral link with Iranians, as both Iranians and Indo-Aryans are 339 descendants of the Indo-Iranian branch of the Indo-European language family [23,24,40]. The 340 absence of the E545K mutation, may thus be tied to ancestral roots, and consequent genetic 341 backgrounds, among other possible factors. This provides valuable preliminary data from Sri 342 Lanka, contributing to the global effort of cataloging *PIK3CA* mutations, which are highly 343 heterogeneous across populations with different ancestral origins [10].

344 The significant association between patient ancestry and the presence of a *PIK3CA* mutation 345 (p=0.028), where the Indo-Aryan and Dravidian ancestries could potentially be associated with 346 differing rates of PIK3CA mutations, suggests that ancestral influence tied to ethnic 347 backgrounds could affect the occurrence of *PIK3CA* mutations in Sri Lanka as well as in South Asia. Though the strength of this observation is hampered by the small sample size, particularly 348 349 with respect to the patients of Dravidian origin (one Tamil and one Moor in the entire cohort), 350 the presence of *PIK3CA* mutations in both of them cannot be disregarded and warrant further 351 ancestry-oriented mutational analyses. While this association aligns with global findings that 352 somatic *PIK3CA* mutations are linked with ancestry across all cancer types including breast 353 cancer [19-22], our study fills an important gap by investigating these ancestry-specific 354 associations in a cohort, exclusively of South Asian ancestry. These insights may have 355 significant implications for personalized treatment strategies, which may need to be tailored 356 based on the patient's ancestry, as mutation profiles observed in one ancestry may not apply to 357 others – in turn influencing treatment efficacy and outcomes.

Another notable observation was that the *PIK3CA* mutations in the cohort were exclusively seen in SHR+/HER2- luminal tumors, consistent with a similar subtype-specific dominance of

the mutation in previous studies [9]. The molecular mechanisms, including cross talk between the PI3K/AKT/mTOR and ER signaling pathways are postulated to be mediating this, with *PIK3CA* mutations driving oncogenesis via ER signaling, thereby predominating in SHR+ breast cancer subtypes [17].

364 The significant association between PIK3CA mutations and increased likelihood of axillary LN 365 metastasis (p=0.036, OR 9.60) highlights the potential prognostic value of *PIK3CA* mutations 366 in predicting breast cancer progression in the Sri Lankan context. LN metastasis typically 367 indicates a more advanced disease stage, a higher risk of distant metastases and worse 368 outcomes [41]. Therefore, *PIK3CA* mutation testing could guide therapeutic strategies, 369 particularly in decisions related to axillary management and risk assessment, with more 370 intensive therapeutic approaches needed by patients with tumor-positive axillary LNs [42]. 371 Divergent findings in other studies [43], may reflect differences in genetic makeup and lifestyle factors, further emphasizing the need for nuanced molecular investigations in underrepresented 372 373 populations like Sri Lanka.

The absence of associations between clinicopathological features and age group may indicate that other parameters, such as histological grade and Ki67 index, hold greater prognostic value than age, particularly in early-stage breast cancer cohorts [44], like ours. This is supported by the significant association between higher Ki67 indices and an increased risk of developing higher-grade tumors (p=0.024, OR 4.29). These findings further support the use of Ki67 index as a valuable prognostic marker [45] in Sri Lankan breast cancer patients and its importance in clinical decision-making.

381

The striking association between *PIK3CA* mutations and reduced RFS in Sri Lankan breast cancer patients, with high statistical significance (p<0.001, HR 26.19, 95% CI 2.67 – 256.47) suggests that these mutations have a considerable impact on disease prognosis. The broad

confidence interval reflects the small sample size, but even the lower bound presents a significantly increased risk of relapse, nearly three times greater than patients without a *PIK3CA* mutation. This implies a significant impact of *PIK3CA* mutations on disease progression and brings out its potential clinical relevance as a prognostic biomarker in Sri Lankan breast cancer patients. As the first study to analyze *PIK3CA* mutations in Sri Lankan breast cancer patients, our findings are consistent with results from other Asian studies as well as studies on other malignancies, such as colorectal cancer [13,46,47].

392 However, our results did not show mutation-specific associations with RFS, which may be 393 attributed to the smaller cohort size, necessitating further investigation with larger studies. 394 Nevertheless, the predominance of the H1047R mutation- with an observed frequency of 0.81 395 within the total mutations, suggests that it is likely to be responsible for reducing RFS [35] in 396 our cohort, mirroring findings of the aforementioned Iranian study [39]. Given the shared Indo-397 Iranian ancestry of the Sinhalese and Iranians, this parallel may hint at ancestral genetic traits 398 influencing both mutation occurrence and its clinical impact. This further emphasizes the need 399 for nuanced investigations and personalized treatment approaches in populations with specific 400 ancestral backgrounds.

401

402 Our analysis of clinicopathological characteristics also revealed that LN metastasis and Ki67 403 proliferative index are key determinants of relapse risk. Patients with either tumor-positive LNs 404 or a higher Ki67 index (\geq 20%), exhibited a significantly greater hazard of relapse compared to 405 their counterparts without tumor deposits in LNs (p=0.026, HR 123.93) and with lower 406 proliferative indices (p=0.029, HR 79.68). These results reinforce the established role of LN 407 metastasis and cellular proliferation rates as reliable indicators of relapse and survival in breast 408 cancer patients [48-50], while also suggesting underlying molecular mechanisms that

409 contribute to cancer recurrence [50]. This further underscores the importance of these factors410 in staging, prognosis, and therapy of invasive breast cancer in Sri Lankan patients.

411

412 One of the most paramount points in our study is the validation of the observed association 413 between LN metastasis and RFS (p=0.026) by the compounded association of PIK3CA 414 mutations with both LN metastasis (p=0.036) and significantly reduced RFS (p<0.001). This enables us to bridge all three findings. Additionally, the multivariate model demonstrated the 415 416 compounded impact of all these factors (p<0.001) on the likelihood of disease relapse, 417 ultimately emphasizing the importance of considering all three factors- PIK3CA mutations, LN 418 status, and Ki67 index- along with patient ancestry, in prognosis and treatment planning for 419 breast cancer patients in Sri Lanka and across South Asia. This may also suggest an underlying 420 mechanistic link that contributes to the aggressive behavior of breast cancer. It is plausible that 421 in ancestries more prone to the occurrence of PIK3CA mutations in malignant cells, these 422 mutations promote the cancer spread via lymphatic channels, leading to LN metastasis and 423 subsequent recurrence. This progression highlights a crucial step in cancer spread, as LNs 424 function as critical filtering sites within the lymphatic system, where cancer cells infiltrate and 425 establish secondary tumor deposits [52].

426 The above findings align with Stephen Paget's 'Seed and soil hypothesis,' which proposes that 427 metastasis occurs when certain tumor cells (the "seed") preferentially grow in particular organ 428 microenvironments (the "soil") - and that metastases only develop when the right seed is 429 implanted in the right soil [53]. Our study suggests that *PIK3CA* driver mutations, possibly 430 the predominant H1047R mutation, may act as a genetic change that enhances the metastatic 431 potential of breast cancer cells by promoting survival and proliferation. These genetic 432 alterations could facilitate the invasion of lymphatic vessels, leading to the establishment of metastatic colonies in LNs. In this context, *PIK3CA* mutations may assist in planting the "seed" 433

in the "soil" by promoting the establishment of tumor deposits in axillary LNs. Strikingly, further developments to this hypothesis, elaborate how the above mechanisms could result in the primary breast cancer metastasizing to the lungs and bones [54], the exact two organs of relapse diagnosed in our *PIK3CA*-mutated patient population. Therefore, by elucidating this molecular pathway, our study offers valuable insights into the potential role of *PIK3CA* in the underlying biology of aggressive breast cancers, particularly in the Sri Lankan population.

440

441 To our knowledge, PI3K inhibitors are not currently prescribed for breast cancer patients in Sri 442 Lanka. Our study's preliminary observation of a negative prognostic outcome in the 443 predominantly SHR+/HER2-, Sri Lankan breast cancer cohort with *PIK3CA* mutations, serves 444 as a calling out for Sri Lankan clinicians to incorporate PIK3CA mutational testing in routine 445 diagnostic protocols. Patients identified with these mutations could benefit from PI3Ka 446 inhibitors such as Alpelisib, which are approved for this clinical scenario and are known to 447 prolong the RFS in patients [55]. Furthermore, this treatment approach could be tailored for 448 high risk ethnic groups within Sri Lanka (i.e. those with Dravidian ancestry), should a larger 449 study with a better representation of ethnic minority groups, confirm the association of PIK3CA 450 mutations with patient ancestry. This personalized approach could extend beyond breast cancer 451 to other malignancies such as colorectal, gastric, ovarian, and cervical cancers, which have also 452 exhibited PIK3CA mutations and consequent impacts on prognosis [8,56].

453

Despite the significant implications of our study, there are several limitations. The primary limitation is the sample size, which was restricted due to financial and logistical constraints. This limitation impacted the statistical power of several results and affected the ability to perform robust regression and multivariate analyses. Additionally, the retrospective nature of our study also introduced certain constrains. For example, the grouping of patients into broad

459 ancestral categories was based on self-reported ethnicity in hospital records of the patients, 460 rather than genetic testing. Although studies indicate a high concordance between self-reported 461 ancestry and genetic testing results [22], potential misclassification may have oversimplified 462 the complex genetic landscape of the Sri Lankan population. Furthermore, the underrepresentation of minority ethnic groups due to the uneven geographical distribution of 463 464 these populations, greatly impaired the power of the detected association of ancestry with mutation status. Overcoming this limitation might require recruiting patients from a broader 465 466 array of hospitals and oncology clinics around the country, to ensure adequate representation 467 of all ancestral groups.

468 Another limitation is the absence of data on other potentially interacting mutations within the 469 *PIK3CA* gene or in other OGs and TSGs that were not tested in the cohort, and their interplay 470 with the tested mutations. Additionally, the follow-up period in our study was relatively short. All patients with survival data (n=42) were alive, and 90.5% remained recurrence-free within 471 472 5 years post-diagnosis, which limited the survival analysis to RFS as a proxy. A longer follow-473 up period would provide a more comprehensive understanding of long-term outcomes. 474 Nevertheless, this pilot study, the first to analyze *PIK3CA* mutations in relation to breast cancer 475 in different ancestries in Sri Lanka, together with its observed prognostic implications, offers 476 sufficient insight and direction to the chosen objectives, so that a larger, more conclusive study 477 can be conducted to confirm and validate the reported findings. Accordingly, a study on a larger 478 Sri Lankan cohort with a subsequent functional analysis is necessary to address the above 479 limitations, especially to confirm the absence of the E545K mutation in Sri Lankan breast 480 cancer patients and to validate the significance of observed mutations, particularly in the 481 Dravidian population, which appears to be at higher risk based on our findings.

482 **Conclusion**

This study is the first to report on *PIK3CA* mutations in Sri Lankan breast cancer patients, a population with a unique genetic heritage, demonstrating a *PIK3CA* mutation prevalence of 17.46% and significant associations between ancestry-linked mutations, LN metastasis and cancer relapse. Our findings also suggest the existence of a possible molecular link contributing to metastasis.

488 Notably, our observation of a significant association between patient ancestry and PIK3CA 489 mutation status is the first of its kind in an exclusively South Asian cohort. This invites comparisons with similar findings - such as the absence of the E545K mutation - in global 490 491 populations with shared ancestries. Our findings also provide a foundation for prognostic 492 stratification and therapeutic decision-making for breast cancer patients in Sri Lanka - rooted 493 in the presence of *PIK3CA* mutations and patient ancestry - for identifying high-risk patient 494 subsets who may benefit from targeted therapies such as PI3K inhibitors, which are not 495 currently prescribed in Sri Lanka. Further large-scale functional studies are necessary to 496 validate these findings and to improve clinical outcomes for breast cancer patients in Sri Lanka. 497

498 Acknowledgements:

We gratefully acknowledge the invaluable support provided by the staff at the Centre for Immunology and Molecular Biology (CIMB) and the Centre for Transgenic Technologies at the Faculty of Science, University of Colombo, Sri Lanka, as well as the medical laboratory technicians at the Diagnostics Laboratory of University Hospital KDU, Sri Lanka in the completion of the laboratory component of this research.

504 **References:**

505	1.	Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Alqubaishi F, Alnamnakani M, et
506		al. Landscape of somatic mutations in breast cancer: new opportunities for targeted
507		therapies in Saudi Arabian patients. Oncotarget [Internet]. 2021 Mar 30 [cited 2022
508		Mar 24];12(7):686–97. Available from:
509		https://www.oncotarget.com/article/27909/text/
510	2.	Fan L, Goss PE, Strasser-Weippl K. Current Status and Future Projections of Breast
511		Cancer in Asia. Breast Care. 2015;10(6):372-8.
512	3.	Zhukova LG, Andreeva II, Zavalishina LE, Zakiriakhodzhaev AD, Koroleva IA,
513		Nazarenko AV, et al. Breast cancer. Современная онкология [Internet]. 2021 May 1
514		[cited 2023 Jan 16];23(1):5–40. Available from:
515		https://doaj.org/article/30b4e9318d3543faa6dfbfe39ff5c88d
516	4.	Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009
517		Apr;458(7239):719–24.
518	5.	Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M.
519		PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape
520		to Clinical Aspects. International Journal of Molecular Sciences. 2020 Dec
521		26;22(1):173.
522	6.	Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA
523		gene is mutated with high frequency in human breast cancers. Cancer Biology &
524		Therapy. 2004 Aug;3(8):772–5.
525	7.	Samuels Y, Waldman T. Oncogenic Mutations of PIK3CA in Human Cancers.
526		Current Topics in Microbiology and Immunology [Internet]. 2010 [cited 2019 Oct
527		8];21–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164550/

528	8.	Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human
529		cancers. British Journal of Cancer [Internet]. 2006 Jan 31 [cited 2019 Oct
530		8];94(4):455–9. Available from: <u>https://www.nature.com/articles/6602970</u>
531	9.	Reinhardt K, K Stückrath, Hartung C, Kaufhold S, Christoph Uleer, Hanf V, et al.
532		PIK3CA-mutations in breast cancer. Breast cancer research and treatment [Internet].
533		2022 Oct 24;196(3):483–93. Available from:
534		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633529/
535	10.	Chen JW, Murugesan K, Newberg JY, Sokol ES, Savage HM, Stout TJ, et al.
536		Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted
537		Ancestry Populations. JCO Precision Oncology. 2022 Nov;(6).
538	11.	Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are
539		associated with poor outcome. Breast Cancer Research and Treatment. 2005 Nov
540		30;96(1):91–5.
541	12.	Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers
542		resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis
543		and activating the PI3K/AKT/mTOR signaling pathway. Annals of Translational
544		Medicine [Internet]. 2021 Mar 1 [cited 2021 Dec 21];9(5):410-0. Available from:
545		https://atm.amegroups.com/article/view/64371/html
546	13.	Cho YA, Ko SY, Suh YJ, Kim S, Park JH, Park HR, et al. PIK3CA Mutation as
547		Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who
548		Received Adjuvant Chemotherapy. Current Oncology. 2022 Apr 19;29(5):2895–908.
549	14.	Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, et al. PIK3CA
550		mutation status, progression and survival in advanced HR + /HER2- breast cancer: a
551		meta-analysis of published clinical trials. BMC Cancer. 2022 Sep 21;22(1).

552	15	. Zagami P, Aranzazu Fernandez-Martinez, Rashid NU, Hoadley KA, Spears PA,
553		Curigliano G, et al. Association of PIK3CA Mutation With Pathologic Complete
554		Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-
555		Stage ERBB2/HER2-Positive Breast Cancer. JAMA Network Open. 2023 Dec
556		20;6(12):e2348814-4.
557	16	. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, et al.
558		PIK3CA mutation impact on survival in breast cancer patients and in ER α , PR and
559		ERBB2-based subgroups. Breast Cancer Research : BCR [Internet]. 2012;14(1):R28.
560		Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496146/
561	17	. Zardavas D, te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, et al.
562		Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled
563		Analysis of Individual Patient Data. Journal of Clinical Oncology. 2018 Apr
564		1;36(10):981–90.
565	18	. Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Sanni A, et al. Germline variants
566		and somatic mutation signatures of breast cancer across populations of African and
567		European ancestry in the US and Nigeria. International Journal of Cancer. 2019 Jun
568		7;145(12):3321–33.
569	19	. Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, et al.
570		Characterization of Nigerian breast cancer reveals prevalent homologous
571		recombination deficiency and aggressive molecular features. Nature Communications
572		[Internet]. 2018 Oct 16 [cited 2021 Sep 22];9(1):4181. Available from:
573		https://www.nature.com/articles/s41467-018-06616-0#Sec10
574	20	. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, et al. Comparison of
575		the Genomic Landscape Between Primary Breast Cancer in African American Versus

576		White Women and the Association of Racial Differences With Tumor Recurrence.
577		Journal of Clinical Oncology. 2015 Nov 1;33(31):3621-7.
578	21.	Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C,
579		et al. Comprehensive analysis of genetic ancestry and its molecular correlates in
580		cancer. Cancer Cell. 2020 May;37(5). doi:10.1016/j.ccell.2020.04.012
581	22.	Arora K, Tran TN, Kemel Y, Miika Mehine, Liu YL, Subhiksha Nandakumar, et al.
582		Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical
583		Cancer Sequencing Cohort. Cancer Discovery. 2022 Sep 1;12(11):2552-65.
584	23.	Perera N, Galhena G, Ranawaka G. X-chromosomal STR based genetic
585		polymorphisms and demographic history of Sri Lankan ethnicities and their
586		relationship with global populations. Scientific Reports. 2021 Jun 17;11(1).
587	24.	Singh PP., Kumar S, Pasupuleti N, Weerasooriya PR, van Driem G, Tennekoon KH,
588		et al. Reconstructing the population history of Sinhalese, the major ethnic group in $\mathrm{\acute{S}r\bar{I}}$
589		Lańkā. iScience [Internet]. 2023 Oct 1;26(10):107797-7. Available from:
590		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514440/
591	25.	Vithana PVSC, Dheerasinghe DSAF, Handagiripathira HMI, Alahapperuma S,
592		Nilaweera I, Perera S. Sri Lankan Patterns of Female Cancers: Incidence and
593		Mortality Over 1995-2010. Asian Pacific Journal of Cancer Care. 2021 Mar
594		26;6(1):27–33.
595	26.	Fernando A, Jayarajah U, Prabashani S, Fernando EA, Seneviratne SA. Incidence
596		trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer
597		database. BMC Cancer. 2018 Apr 27;18(1).
598	27.	Anwar SL, Raharjo CA, Herviastuti R, Dwianingsih EK, Setyoheriyanto D, Avanti
599		WS, et al. Pathological profiles and clinical management challenges of breast cancer

600		emerging in young women in Indonesia: a hospital-based study. BMC Women's
601		Health. 2019 Feb 6;19(1).
602	28.	Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. International
603		Journal of Surgery. 2010;8(6):448-52. doi:10.1016/j.ijsu.2010.05.012
604	29.	Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam
605		M, et al. Clinicopathological Characteristics And Treatment Outcomes Of Breast
606		Cancer Among Adolescents And Young Adults In A Developing Country. Cancer
607		Management and Research. 2019 Nov 1;Volume 11:9891-7.
608	30.	Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is Breast Cancer
609		the Same Disease in Asian and Western Countries? World Journal of Surgery
610		[Internet]. 2010 [cited 2021 May 28];34(10):2308–24. Available from:
611		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936680/
612	31.	Balawardena J, Skandarajah T, Rathnayake W, Joseph N. Breast Cancer Survival in
613		Sri Lanka. JCO Global Oncology. 2020 Apr;(6):589-99.
614	32.	Perera R, Senanayake A, Balawardana J, Malviarachchi S, Kumarasinghe I, De Silva
615		A. Clinicopathological analysis of breast cancers in a single unit of a Sri Lankan
616		tertiary care hospital. Sri Lanka Journal of Cancer [Internet]. 2023;3(1):27-35.
617		Available from: https://slco.lk/wp-content/uploads/2023/09/j5.pdf
618	33.	Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US
619		Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2
620		Status. JNCI: Journal of the National Cancer Institute [Internet]. 2014 Apr 28;106(5).
621		Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580552/
622	34.	Ahmad F, Badwe A, Verma G, Bhatia S, Das BR. Molecular evaluation of PIK3CA
623		gene mutation in breast cancer: determination of frequency, distribution pattern and

624		its association with clinicopathological findings in Indian patients. Medical Oncology.
625		2016 Jun 9;33(7).
626	35.	Mangone F, Bobrovnitchaia I, Salaorni S, Manuli E, Nagai M. PIK3CA exon 20
627		mutations are associated with poor prognosis in breast cancer patients. Clinics. 2012
628		Nov 7;67(11):1285–90.
629	36.	Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20
630		mutation is independently associated with a poor prognosis in breast cancer patients.
631		Annals of Surgical Oncology [Internet]. 2008 Apr 1 [cited 2020 Nov 24];15(4):1064–
632		9. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/18183466/</u>
633	37.	Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, et al.
634		Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast
635		Cancer Research. 2020 May 13;22(1).
636	38.	Chao T, Tsai Y, Liu C, Lien PJ, Lin Y, Feng CJ, et al. Prevalence of PIK3CA
637		mutations in Taiwanese patients with breast cancer: a retrospective next-generation
638		sequencing database analysis. Frontiers in Oncology [Internet]. 2023 Aug 15 [cited
639		2024 Jan 24];13. Available from:
640		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466395/
641	39.	Nazeri E, Parniani M, Olfatbakhsh A, Najafi S, Peyman M, Karami B, et al.
642		Evaluation of PIK3CA Gene Mutations in Breast Cancer Patients Treated by
643		Trastuzumab. Archives of Breast Cancer. 2023 Jun 16;248–55.
644	40.	Indo-Iranian languages [Internet]. Encyclopedia Britannica. Available from:
645		https://www.britannica.com/topic/Indo-Iranian-languages
646	41.	Luo M, Lin X, Hao D, Kangle Wang Shen, Wu W, Wang L, et al. Incidence and risk
647		factors of lymph node metastasis in breast cancer patients without preoperative
648		chemoradiotherapy and neoadjuvant therapy: analysis of SEER data. Gland Surgery

- 649 [Internet]. 2023 Nov 1 [cited 2024 Aug 27];12(11):1508–24. Available from:
- 650 <u>https://pubmed.ncbi.nlm.nih.gov/38107495/</u>
- 42. Rao R. The Evolution of Axillary Staging in Breast Cancer. PubMed. 2015 Nov
 27:112(5):385–8.
- 43. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA
 Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer
 Research. 2009 Aug 11;15(16):5049–59.
- 44. Arikan AE, Kara H, Dülgeroğlu O, Erdoğan EN, Capkinoglu E, Uras C. Do
- 657 prognosis and clinicopathological features differ in young early-stage breast cancer?
- Frontiers in Surgery [Internet]. 2022 Oct 19 [cited 2024 Sep 29];9. Available from:
- 659 <u>https://doi.org/10.3389/fsurg.2022.900363</u>
- 45. Kanyılmaz G, Yavuz BB, Aktan A, Karaağaç M, Uyar M, Fındık S. Prognostic
- 661 Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic
- Factors European Journal of Breast Health [Internet]. Doi.org. 2019 [cited 2024 Sep

663 29]. Available from: <u>https://doi.org/10.5152/ejbh.2019.4778</u>

- 46. Deng L, Zhu X, Sun Y, Wang J, Zhong X, Li J, et al. Prevalence and Prognostic Role
- of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. Cancer Research and
 Treatment. 2019 Jan 15;51(1):128–40.
- 47. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, et al. PIK3CA mutation
 is predictive of poor survival in patients with colorectal cancer. International Journal
 of Cancer. 2007;121(8):1771–8.
- 48. Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic
- 671 factors in metaplastic carcinoma of the breast: a multi-institutional study. British
- 672 Journal of Cancer. 2014 Nov 25;112(2):283–9.

- 49. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma
- 674 [Internet]. 2018 Jun 1;127(2):175–86. Available from:
- 675 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945335/</u>
- 50. Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of
- breast cancer: triple negative tumours are more likely lymph node negative.
- 678 Oncotarget. 2017 Feb 2;8(33).
- 51. Hao Y, Baker D, ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition
- and Cancer Metastasis. International Journal of Molecular Sciences [Internet]. 2019
- 681 Jun 5;20(11):2767. Available from:
- 682 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600375/</u>
- 52. Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, et al. Lymph node metastasis in cancer
- 684 progression: molecular mechanisms, clinical significance and therapeutic
- 685 interventions. Signal Transduction and Targeted Therapy [Internet]. 2023 Sep 27
- 686 [cited 2023 Sep 29];8(1):1–33. Available from:
- 687 <u>https://www.nature.com/articles/s41392-023-01576-4</u>
- 53. Paget S. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF
- 689 THE BREAST. The Lancet. 1889 Mar;133(3421):571–3.
- 690 54. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-The role of tumor-
- 691 stroma interactions in metastasis to different organs. International Journal of Cancer.
- 692 2011 Mar 25;128(11):2527–35.
- 55. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib
- 694 for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New
- 695 England Journal of Medicine. 2019 May 16;380(20):1929–40.

- 696 56. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA Mutation
- 697 Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon
- 698 Cancer. Journal of Clinical Oncology. 2009 Mar 20;27(9):1477–84.

699

700 Supporting Information

- 701 S1 Fig. Ethical approval for the study granted by the Ethics Review Committee of the
- 702 Institute of Biology, Sri Lanka (ERC IOBSL 303 07 2023)
- 703 S2 Fig. Age distribution of the cohort
- 704 S3 Fig. Distribution of tumor size (cm) in the cohort
- 705 S1 Table. Grouping of the variables used for the data analysis
- 706 S2 Table. Status of lymph node (LN) metastasis and patient age group in selected clinical
- 707 and histopathological groups









n=63

No survival data available

Survival analysis
(based on follow-up data upto 5 years from diagnosis)
$$n=42$$

Figure 1



Figure 2 (A, B, C and D)



Figure 2A





Figure 2B

Strata 🕂 Ki67=0 🕂 Ki67=1



Figure 2C



Figure 2D